Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

Philip D. Bonomi, MD
Published: Friday, Oct 06, 2017



Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non–small cell lung cancer (NSCLC).

Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.

If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
 
SELECTED
LANGUAGE


Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non–small cell lung cancer (NSCLC).

Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.

If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x